Trials / Completed
CompletedNCT00753649
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa Vaccine in Healthy Infants
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 224 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 6 Weeks – 12 Weeks
- Healthy volunteers
- Accepted
Summary
This study will evaluate GSK Biologicals' DTPa-HBV-IPV/Hib vaccine given as a three-dose primary vaccination course at 2, 4 and 6 months of age, in terms of safety and immunogenicity in different population of infants residing in Canada.
Detailed description
This protocol posting has been updated following Protocol amendment 1 (19-MAY-2010).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Infanrix™ hexa | Intramuscular, three doses |
Timeline
- Start date
- 2008-09-23
- Primary completion
- 2013-03-12
- Completion
- 2013-03-12
- First posted
- 2008-09-16
- Last updated
- 2019-11-27
- Results posted
- 2016-11-30
Locations
3 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00753649. Inclusion in this directory is not an endorsement.